

Roberto M Lemoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10958604/publications.pdf>

Version: 2024-02-01

107
papers

6,524
citations

66343

42
h-index

66911

78
g-index

108
all docs

108
docs citations

108
times ranked

8144
citing authors

#	ARTICLE	IF	CITATIONS
1	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	27.0	1,407
2	Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. <i>Blood</i> , 2002, 100, 230-237.	1.4	393
3	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 ^{hi} into CD25 ^{lo} T regulatory cells. <i>Blood</i> , 2007, 109, 2871-2877.	1.4	357
4	The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. <i>Blood</i> , 2009, 113, 2394-2401.	1.4	237
5	Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10 ^{hi} /IL-12 ^{low/neg} accessory cells with dendritic-cell features. <i>Blood</i> , 2006, 108, 218-227.	1.4	226
6	Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2273-2281.	1.6	153
7	Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. <i>Immunology Letters</i> , 2004, 94, 11-26.	2.5	134
8	Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow-Derived Mesenchymal Stem Cells. <i>Stem Cells</i> , 2006, 24, 454-461.	3.2	123
9	Extracellular ATP Exerts Opposite Effects on Activated and Regulatory CD4 ⁺ T Cells via Purinergic P2 Receptor Activation. <i>Journal of Immunology</i> , 2012, 189, 1303-1310.	0.8	121
10	Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN- γ . <i>European Journal of Immunology</i> , 2004, 34, 1291-1302.	2.9	120
11	Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. <i>Blood</i> , 2004, 104, 1662-1670.	1.4	111
12	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1914-1921.	7.0	110
13	Cycling Status of CD34 ⁺ Cells Mobilized Into Peripheral Blood of Healthy Donors by Recombinant Human Granulocyte Colony-Stimulating Factor. <i>Blood</i> , 1997, 89, 1189-1196.	1.4	106
14	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	4.1	106
15	Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. <i>Haematologica</i> , 2010, 95, 2022-2030.	3.5	95
16	Extracellular Purines Promote the Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells to the Osteogenic and Adipogenic Lineages. <i>Stem Cells and Development</i> , 2013, 22, 1097-1111.	2.1	95
17	The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. <i>Blood</i> , 2007, 109, 533-542.	1.4	93
18	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016, 127, 1138-1150.	1.4	89

#	ARTICLE	IF	CITATIONS
19	Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. <i>Experimental Hematology</i> , 2006, 34, 879-887.	0.4	88
20	Interleukin-11 induces Th2 polarization of human CD4+ T cells. <i>Blood</i> , 2001, 97, 2758-2763.	1.4	85
21	The sixth sense: hematopoietic stem cells detect danger through purinergic signaling. <i>Blood</i> , 2012, 120, 2365-2375.	1.4	83
22	Mobilization of Bone Marrow-Derived Hematopoietic and Endothelial Stem Cells After Orthotopic Liver Transplantation and Liver Resection. <i>Stem Cells</i> , 2006, 24, 2817-2825.	3.2	79
23	Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. <i>British Journal of Haematology</i> , 1992, 81, 203-211.	2.5	77
24	Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. <i>Experimental Hematology</i> , 2011, 39, 360-374.e5.	0.4	73
25	The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells. <i>Journal of Immunology</i> , 2014, 192, 1231-1240.	0.8	72
26	Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. <i>Clinical Cancer Research</i> , 2022, 28, 2753-2761.	7.0	70
27	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. <i>Blood</i> , 2000, 95, 2234-2239.	1.4	66
28	In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. <i>British Journal of Haematology</i> , 2000, 110, 351-361.	2.5	65
29	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 ⁺ cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009, 114, 5191-5200.	1.4	62
30	Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. <i>Haematologica</i> , 2005, 90, 225-31.	3.5	62
31	Stem Cell Factor and FLT3-Ligand Are Strictly Required to Sustain the Long-Term Expansion of Primitive CD34 ⁺ DR ⁺ Dendritic Cell Precursors. <i>Journal of Immunology</i> , 2001, 166, 848-854.	0.8	61
32	Generation and functional characterization of human dendritic cells derived from CD34 ⁺ cells mobilized into peripheral blood: comparison with bone marrow CD34 ⁺ cells. <i>British Journal of Haematology</i> , 1998, 101, 756-765.	2.5	60
33	Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class II-restricted peptides. <i>British Journal of Haematology</i> , 2007, 139, 415-424.	2.5	58
34	PGE ₂ -Induced IDO1 Inhibits the Capacity of Fully Mature DCs to Elicit an In Vitro Antileukemic Immune Response. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	2.2	53
35	Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. <i>Blood</i> , 2012, 119, 217-226.	1.4	52
36	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents. <i>Haematologica</i> , 2018, 103, 80-90.	3.5	48

#	ARTICLE	IF	CITATIONS
37	Efficient presentation of tumor idiotype to autologous T cells by CD83+ dendritic cells derived from highly purified circulating CD14+ monocytes in multiple myeloma patients. <i>Experimental Hematology</i> , 2000, 28, 931-940.	0.4	46
38	The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. <i>Oncotarget</i> , 2017, 8, 2261-2274.	1.8	46
39	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	1.7	46
40	The Kinetic Status of Hematopoietic Stem Cell Subpopulations Underlies a Differential Expression of Genes Involved in Self-Renewal, Commitment, and Engraftment. <i>Stem Cells</i> , 2005, 23, 496-506.	3.2	45
41	Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. <i>Oncotarget</i> , 2017, 8, 5895-5908.	1.8	45
42	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. <i>Experimental Hematology</i> , 2005, 33, 1521-1530.	0.4	44
43	Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. <i>British Journal of Haematology</i> , 2003, 121, 240-250.	2.5	43
44	Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. <i>British Journal of Haematology</i> , 1994, 88, 760-769.	2.5	42
45	Generation of Dendritic Cells from Positively Selected CD14+ Monocytes for Anti-tumor Immunotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 1419-1428.	1.3	40
46	Hematopoietic stem cell mobilization. <i>Haematologica</i> , 2008, 93, 321-324.	3.5	38
47	Immunotoxins Containing Recombinant Anti-CTLA-4 Single-Chain Fragment Variable Antibodies and Saporin: In Vitro Results and In Vivo Effects in an Acute Rejection Model. <i>Journal of Immunology</i> , 2001, 167, 4222-4229.	0.8	34
48	Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. <i>Blood</i> , 2003, 102, 1595-1600.	1.4	33
49	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	5.2	33
50	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 1880-1887.	4.1	31
51	Rapid Induction of CD40 on a Subset of Granulocyte Colony-Stimulating Factor-Mobilized CD34+ Blood Cells Identifies Myeloid Committed Progenitors and Permits Selection of Nonimmunogenic CD40+ Progenitor Cells. <i>Blood</i> , 1999, 94, 2293-2300.	1.4	30
52	Concomitant Mobilization of Plasma Cells and Hematopoietic Progenitors into Peripheral Blood of Patients with Multiple Myeloma. <i>Stem Cells and Development</i> , 1996, 5, 339-349.	1.0	26
53	Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 113, 391-399.	2.5	26
54	Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis. <i>Stem Cell Research and Therapy</i> , 2015, 6, 170.	5.5	26

#	ARTICLE	IF	CITATIONS
55	Combining flow cytometry and <i>WT1</i> assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e348-e351.	3.5	26
56	Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. <i>British Journal of Haematology</i> , 1999, 107, 419-428.	2.5	25
57	Stem cell plasticity: time for a reappraisal?. <i>Haematologica</i> , 2005, 90, 360-81.	3.5	25
58	Selection and Transplantation of Autologous Hematopoietic CD34+ Cells for Patients with Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1997, 26, 1-11.	1.3	24
59	The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling. <i>Experimental Hematology</i> , 2015, 43, 974-985.e1.	0.4	24
60	Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1224-1232.	2.0	23
61	NEW STRATEGIES FOR STEM CELL MOBILIZATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012066.	1.3	22
62	Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial. <i>Digestive and Liver Disease</i> , 2015, 47, 1059-1066.	0.9	22
63	The CD47 pathway is deregulated in human immune thrombocytopenia. <i>Experimental Hematology</i> , 2011, 39, 486-494.	0.4	21
64	CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1. <i>Experimental Hematology</i> , 2015, 43, 268-276.e5.	0.4	21
65	Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors. <i>Experimental Hematology</i> , 2013, 41, 102-112.	0.4	19
66	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. <i>Clinical Cancer Research</i> , 2016, 22, 6099-6109.	7.0	19
67	Amino acid depletion triggered by γ -asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. <i>Blood Advances</i> , 2020, 4, 4312-4326.	5.2	19
68	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	2.5	19
69	Interleukin-11 (IL-11) acts as a synergistic factor for the proliferation of human myeloid leukaemic cells. <i>British Journal of Haematology</i> , 1995, 91, 319-326.	2.5	18
70	Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation. <i>British Journal of Haematology</i> , 1994, 86, 97-105.	2.5	16
71	C-kit ligand (SCF) in human multiple myeloma cells. <i>Leukemia and Lymphoma</i> , 1996, 20, 457-464.	1.3	16
72	Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. <i>Experimental Hematology</i> , 1999, 27, 1255-1263.	0.4	16

#	ARTICLE	IF	CITATIONS
73	Impaired Dendritic Cell Immunophenotype and Function in Heart Transplant Patients Undergoing Active Cytomegalovirus Infection. <i>Transplantation</i> , 2005, 79, 219-227.	1.0	16
74	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	4.1	14
75	Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (<scp>FLAI</scp>) provides the most useful prognostic information. <i>British Journal of Haematology</i> , 2019, 184, 457-460.	2.5	13
76	Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34 ⁺ human stem cells. <i>British Journal of Haematology</i> , 2003, 123, 720-729.	2.5	12
77	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. <i>Haematologica</i> , 2020, 105, 2420-2431.	3.5	12
78	EVIDENCE THAT LONG-TERM BONE MARROW CULTURE OF PATIENTS WITH MULTIPLE MYELOMA FAVORS NORMAL HEMOPOIETIC PROLIFERATION. <i>Transplantation</i> , 1989, 48, 1026-1030.	1.0	11
79	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	1.8	10
80	Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. <i>British Journal of Haematology</i> , 1998, 101, 119-129.	2.5	9
81	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTIMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	2.8	9
82	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418.	1.7	9
83	Interleukin-9 in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1997, 26, 563-573.	1.3	8
84	Dendritic Cell Differentiation. <i>Journal of Immunology</i> , 2004, 172, 3-4.	0.8	6
85	The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	2.2	6
86	Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment. <i>Haematologica</i> , 2022, 107, 1410-1426.	3.5	6
87	Interleukin-12 Gene Expression into Acute Myeloid Leukemia-Derived Dendritic Cells Overcomes T-Cell Functional Impairment Induced by Leukemic Microenvironment.. <i>Blood</i> , 2004, 104, 1816-1816.	1.4	6
88	Measurable Residual Disease in High-Risk Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 1278.	3.7	6
89	Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia. <i>Experimental Hematology</i> , 2017, 45, 10-16.	0.4	5
90	First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. <i>Blood</i> , 2021, 138, 1474-1474.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters. <i>Frontiers in Immunology</i> , 2021, 12, 804988.	4.8	5
92	Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 33, 172-173.	0.7	4
93	Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product. <i>Journal of Translational Medicine</i> , 2022, 20, 14.	4.4	4
94	The timing of plerixafor addition to G-CSf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 946-954.	2.4	3
95	Thrombopoietin, Interleukin-11, and Early-Acting Megakaryocyte Growth Factors in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 2000, 40, 179-190.	1.3	2
96	Improvement of human myeloma stem cell growth in a liquid culture system supplemented with phytohemagglutinin. <i>International Journal of Cell Cloning</i> , 1988, 6, 313-323.	1.6	1
97	Purinergic Signaling Modulates Human Bone Marrow-Derived Mesenchymal Stem Cells Function.. <i>Blood</i> , 2009, 114, 1441-1441.	1.4	1
98	The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis. <i>Blood</i> , 2015, 126, 2394-2394.	1.4	1
99	The therapeutic role of dendritic cells in cancer immunotherapy. <i>Haematologica</i> , 2002, 87, 62-6.	3.5	1
100	Exploiting tumor vulnerabilities: NAD ⁺ -depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 897-898.	2.4	0
101	Purification of Allogeneic Idiotype-Specific T Lymphocytes According to IFN- γ Production for Adoptive Immunotherapy in Multiple Myeloma Patients.. <i>Blood</i> , 2004, 104, 2119-2119.	1.4	0
102	Hepatocyte Growth Factor (HGF) Favors Monocyte Differentiation into Interleukin (IL)-10+IL-12neg Regulatory Dendritic Cells.. <i>Blood</i> , 2005, 106, 2297-2297.	1.4	0
103	In Vitro and In Vivo Induction of Human Hematopoietic Stem Cell Migration by Extracellular UTP.. <i>Blood</i> , 2005, 106, 1730-1730.	1.4	0
104	Acute Myeloid Leukemia-Derived Dendritic Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-dioxygenase.. <i>Blood</i> , 2006, 108, 1899-1899.	1.4	0
105	Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2012, 120, 3733-3733.	1.4	0
106	Human Blood Dendritic Cells Induce Tregs Through the PGE2-Independent Expression of an Active Form of IDO2 Enzyme. <i>Blood</i> , 2012, 120, 1047-1047.	1.4	0
107	Pegfilgrastim for mobilization of stem cells in allogeneic donors. <i>Haematologica</i> , 2005, 90, 1590A.	3.5	0